Venous Thrombotic Events in Cancer: The Bottom Line

The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest. 2004; 126(3 suppl).

Heit J.A. , O'Fallon W.M. , Petterson T.M. . Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 4: 1245–1248.

Blom J.W. , Doggen C.J. , Osanto S. . Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 4: 715–722.

Lee A.Y. , Julian J.A. , Levine M.N. . Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999; 4: 417–423.

Bick R.L. . Cancer-associated thrombosis. N Engl J Med. 2003; 4: 109–110.

Heit J.A. . Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005; 4(suppl 1): 5–10.

Miller G.J. , Bauer K.A. , Howarth D.J. . Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost. 2004; 2: 2107–2114.

Schulman S. , Lindmarker P. . Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism: duration of anticoagulation trial. N Engl J Med. 2000; 342: 1953–1958.

Sorensen H.T. , Mellemkjaer L. , Olsen J.H. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Heit J.A. , Silverstein M.D. , Mohr D.N. . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 4: 809–815.

Sorensen H.T. , Mellemkjaer L. , Nielsen G.L. . Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 4: 1846–1850.

Levitan N. , Dowlati A. , Remick S.C. . Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999; 78: 285–291.

Levesque H. , Belizna C. , Michel P. . Venous thromboembolic treatment in patients with cancer (in French). Rev Med Interne. 2004; 4: 906–914.

Kakkar A.K. , Levine M. , Pinedo H.M. . Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003; 4: 381–388.

Lee A.Y. , Levine M.N. , Baker R.I. . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 4: 146–153.

Sallah S. , Wan J.Y. , Nguyen N.P. . Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002; 4: 575–579.

Thodiyil P.A. , Kakkar A.K. . Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002; 4: 1076–1077.

Geerts W.H. , Pineo G.F. , Heit J.A. . Prevention of venous thromboembolism. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 338S–400S.

Bergqvist D. , Burmark U.S. , Flordal P.A. . Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg. 1995; 4: 496–501.

Rasmussen M.S. . Does prolonged thromboprophylaxis improve outcome in patients undergoing surgery? Cancer Treat Rev. 2003; 4(suppl 2): 15–17.

ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997; 84: 1099–1103.

Alikhan R. , Cohen A.T. , Combe S. . Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003; 4: 341–346.

Bauersachs R.M. . Fondaparinux: an update on new study results. Eur J Clin Invest. 2005; 4(suppl 1): 27–32.

Bonthier J. . The venous thrombotic risk in non-surgical patients. Drugs. 1996; 4(suppl): 16–29.

Alikhan R. , Peters F. , Wilmott R. . Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004; 4: 1254–1257.

Masci G. , Magagnoli M. , Zucali P.A. . Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol. 2003; 4: 736–739.

Reichart P. , Kretzschmar A. , Biakhov M. . A phase III double-blind, placebo-controlled study evaluating the efficacy and safety of daily low-molecular-weight heparin (dalteparin sodium, Fragmin) in preventing catheter-related complications in cancer patients with central venous catheters. Proc Annu Meet Am Soc Clin Oncol. 2002; 4: 1474. Abstract.

Hirsh J. , Raschke R. . Heparin and low-molecular-weight heparin. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 4(3 suppl): 188S–203S.

Baum M. . Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control. 2004; 4: 217–221.

Buller H.R. , Agnelli G. , Hull R.D. . Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Consensus Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl): 401S–428S. Erratum in: Chest. 2005; 4: 416.

Hull R.D. , Pineo G.F. , Mah A.F. . A randomized trial evaluating longterm low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood. 2002; 4: 148a. Abstract.

Kakkar A.K. . Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control. 2005; 4(suppl 1): 22–30.